Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Entegris Inc (ENTG) vs Eli Lilly And Co (LLY) Price & Performance

Entegris IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Entegris Inc vs Eli Lilly And Co — how do they compare? Entegris Inc trades at $162 (market cap $22.95B), while Eli Lilly And Co trades at $1,217.62 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 47.1× Entegris Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.

ENTGLLY
Market Cap
$22.95B$1.08T
Sector
TechnologyHealth
52-Week High
$184.00$1.24K
52-Week Low
$68.80$639.43
Enterprise Value
$26.16B$1.13T
Dividend Yield
0.27%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Entegris Inc

ENTG trades at $159.66, up 10.71% in 24 hours, reflecting strong momentum driven by Q2 2026 earnings beats and AI-driven semiconductor demand. The stock is near its 52-week high with bullish technical indicators and a consensus price target of $188.67. Revenue growth and margin expansion highlight operational strength, though elevated P/E and P/S ratios signal high valuation expectations.

Outlook is positive with continued earnings growth potential from semiconductor industry tailwinds, but risks include valuation sensitivity and competitive pressures. The stock offers upside to analyst targets but requires monitoring of execution and market volatility.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY